Gurbuz Ahmet Tayfun, Zia Ayhan A, Cui Haiyan, Sasmazel Ahmet, Ates Gursel, Aytac Aydin
Department of Cardiothoracic Surgery and Cardiology, Anadolu Foundation Health Care Systems/Johns Hopkins Medicine, Kocaeli, Turkey.
J Card Surg. 2006 Jan-Feb;21(1):28-34. doi: 10.1111/j.1540-8191.2006.00166.x.
Off-pump coronary artery bypass (OPCAB) grafting is gaining popularity; however, decreased mid-term graft patency and increased coronary reintervention rates are reported.
Five hundred and ninety-one consecutive unselected patients underwent OPCAB grafting from February 2000 to April 2004 (mean follow-up 38.54 +/- 0.54 months). One hundred and thirteen patients had < or =2 grafts, and four hundred and seventy-eight had > or =3 grafts. At least one radial artery graft was present in 398 patients, 328 received postoperative Clopidogrel, and 391 received postoperative statins. History of at least one percutaneous coronary intervention (PCI) was present in 192 patients.
Twenty-nine patients developed recurrent angina, nine had myocardial infraction, and twenty underwent coronary reintervention. Five patients died of sudden cardiac death. Overall mortality was 4.9% during follow-up (29 patients). Postoperative Clopidogrel and statins as well as intraoperative shunt use significantly decreased symptom recurrence and adverse cardiac events. Diabetes, chronic obstructive pulmonary disease, prior history of PCI, and utilization of radial artery grafts were positive predictors of symptom recurrence and adverse cardiac events. Utilization of radial artery grafts, history of PCI as well as low preoperative ejection fraction increased mortality. Number of bypass grafts, type of conduit, grafted territory, hyperlipidemia, or prior coronary artery bypass graft surgery (CABG) did not influence symptom recurrence, adverse cardiac events or mortality.
OPCAB grafting can be performed with low symptom recurrence, adverse cardiac events, and mortality rates. Modification of intra- and postoperative management strategies may improve outcomes.
非体外循环冠状动脉搭桥术(OPCAB)正日益普及;然而,有报道称其术后中期移植血管通畅率下降且冠状动脉再次干预率增加。
2000年2月至2004年4月期间,591例未经选择的连续患者接受了OPCAB手术(平均随访38.54±0.54个月)。113例患者有≤2支移植血管,478例患者有≥3支移植血管。398例患者至少有1支桡动脉移植血管,328例患者术后接受氯吡格雷治疗,391例患者术后接受他汀类药物治疗。192例患者有至少1次经皮冠状动脉介入治疗(PCI)史。
29例患者出现复发性心绞痛,9例发生心肌梗死,20例接受冠状动脉再次干预。5例患者死于心源性猝死。随访期间总死亡率为4.9%(29例患者)。术后使用氯吡格雷和他汀类药物以及术中使用分流管可显著降低症状复发率和不良心脏事件发生率。糖尿病、慢性阻塞性肺疾病、既往PCI史以及使用桡动脉移植血管是症状复发和不良心脏事件的阳性预测因素。使用桡动脉移植血管、PCI史以及术前低射血分数会增加死亡率。搭桥血管数量、血管桥类型、搭桥区域、高脂血症或既往冠状动脉搭桥术(CABG)均不影响症状复发、不良心脏事件或死亡率。
OPCAB手术可在低症状复发率、不良心脏事件发生率和死亡率的情况下进行。调整术中和术后管理策略可能会改善预后。